I am always on the lookout for information about new treatments and therapies for Bipolar Disorder. CNN is reporting today that the biopharmaceutical company Repligen has shown positive results from trials of their new drug RG2417 for treatement of Bipolar Disorder.
"We are pleased with the results of this study which provides substantial evidence of efficacy of RG2417 in improving the symptoms of bipolar disorder," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "The results of this study support further evaluation of RG2417 in this patient population and will be useful in the design of future clinical studies."
It is encouraging that studies are taking place that help drug companies and physicians better understand Bipolar Disorder and that new treatments are possible. Hopefully, in the future, Bipolar Disorder may be more effectively treated.
Read the full article here: Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
No comments:
Post a Comment